[go: up one dir, main page]

CL2008003197A1 - Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer. - Google Patents

Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.

Info

Publication number
CL2008003197A1
CL2008003197A1 CL2008003197A CL2008003197A CL2008003197A1 CL 2008003197 A1 CL2008003197 A1 CL 2008003197A1 CL 2008003197 A CL2008003197 A CL 2008003197A CL 2008003197 A CL2008003197 A CL 2008003197A CL 2008003197 A1 CL2008003197 A1 CL 2008003197A1
Authority
CL
Chile
Prior art keywords
antibody
beta8
hybridoma
mammal
vitro
Prior art date
Application number
CL2008003197A
Other languages
English (en)
Inventor
E Vanmechelen
P Gronet
N Sergeant
M Gompel
A Delacourte
L Buee
L Pradier
V Blanchard-Bregeon
Original Assignee
Innogenetics Nv
Inst Nat Sante Rech Med
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003197(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv, Inst Nat Sante Rech Med, Sanofi Aventis filed Critical Innogenetics Nv
Publication of CL2008003197A1 publication Critical patent/CL2008003197A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Anticuerpo que se une específicamente a la región n-terminal del péptido alfa-beta8-x; hibridoma y proceso de preparación de dicho anticuerpo; método para detectar la carga amiloide in vitro en un mamífero; kit, composición terapéutica y de vacuna que comprenden dicho anticuerpo; uso de dicho anticuerpo para tratar la Enfermedad de Alzheimer.
CL2008003197A 2007-10-29 2008-10-28 Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer. CL2008003197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29

Publications (1)

Publication Number Publication Date
CL2008003197A1 true CL2008003197A1 (es) 2010-01-15

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003197A CL2008003197A1 (es) 2007-10-29 2008-10-28 Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.

Country Status (27)

Country Link
US (1) US8343493B2 (es)
EP (1) EP2205633A1 (es)
JP (1) JP5421277B2 (es)
KR (1) KR20100097651A (es)
CN (1) CN101883792B (es)
AP (1) AP2957A (es)
AR (1) AR069085A1 (es)
AU (1) AU2008317705B2 (es)
CA (1) CA2703825A1 (es)
CL (1) CL2008003197A1 (es)
CO (1) CO6270369A2 (es)
CR (1) CR11396A (es)
EA (1) EA201070539A1 (es)
EC (1) ECSP10010142A (es)
HN (1) HN2010000880A (es)
IL (1) IL205398A0 (es)
MA (1) MA31793B1 (es)
MX (1) MX2010004660A (es)
MY (1) MY155144A (es)
NI (1) NI201000075A (es)
NZ (1) NZ585000A (es)
TN (1) TN2010000197A1 (es)
TW (1) TW200936605A (es)
UA (1) UA103602C2 (es)
UY (1) UY31433A1 (es)
WO (1) WO2009056490A1 (es)
ZA (1) ZA201002989B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
ES2635317T3 (es) * 2007-01-05 2017-10-03 University Of Zurich Anticuerpo anti-beta-amiloide y sus usos
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
EP2847217B1 (en) 2012-05-10 2017-10-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10774120B2 (en) * 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
AU2017299858B2 (en) 2016-07-18 2024-07-25 Promis Neurosciences, Inc. Antibodies to Amyloid beta
US12214056B2 (en) 2016-07-19 2025-02-04 Duke University Therapeutic applications of CPF1-based genome editing
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
EP3672631B9 (en) 2017-08-22 2023-06-28 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
JP7610515B2 (ja) 2018-10-04 2025-01-08 ゲオルク－アウグスト－ウニヴェルジテート ゲッティンゲン シュティフトゥング エッフェントリヒェン レッヒツ，ウニヴェルジテーツメディツィン ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
KR20230016186A (ko) 2020-05-26 2023-02-01 트루바인딩 아이엔씨. 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법
CN118382636A (zh) * 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 一种用于检测淀粉样蛋白β42(Aβ42)的新抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1911765A3 (en) * 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
HN2010000880A (es) 2014-03-10
AR069085A1 (es) 2009-12-30
AU2008317705A1 (en) 2009-05-07
JP2011502139A (ja) 2011-01-20
NI201000075A (es) 2010-09-23
MA31793B1 (fr) 2010-10-01
JP5421277B2 (ja) 2014-02-19
MX2010004660A (es) 2010-07-30
AU2008317705B2 (en) 2014-06-05
ECSP10010142A (es) 2010-07-30
TW200936605A (en) 2009-09-01
EP2205633A1 (en) 2010-07-14
WO2009056490A1 (en) 2009-05-07
IL205398A0 (en) 2010-12-30
CA2703825A1 (en) 2009-05-07
EA201070539A1 (ru) 2010-10-29
KR20100097651A (ko) 2010-09-03
CN101883792B (zh) 2014-08-27
US20110059092A1 (en) 2011-03-10
CO6270369A2 (es) 2011-04-20
UA103602C2 (ru) 2013-11-11
CN101883792A (zh) 2010-11-10
MY155144A (en) 2015-09-15
NZ585000A (en) 2012-08-31
TN2010000197A1 (en) 2011-11-11
ZA201002989B (en) 2011-07-27
CR11396A (es) 2012-10-18
AP2010005249A0 (en) 2010-06-30
US8343493B2 (en) 2013-01-01
AP2957A (en) 2014-08-31
UY31433A1 (es) 2009-05-29

Similar Documents

Publication Publication Date Title
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
CR20150016A (es) Anticuerpo monoclonal
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CL2013002888A1 (es) Anticuerpo que se une peptido antigenico que se obtiene a partir de una proteina tau; composicion farmaceutica que comprende; uso para tratar trastorno o enfermedad neurodegenerativa;kit de ensayo, linea celular (div 2457-2011).
CY1122987T1 (el) Αντισωματα εναντι αμυλοειδους βητα
CL2012001817A1 (es) Anticuerpo monoclonal que reconoce epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos, particularmente a los peptidos abeta amiloides solubles polimericos y peptidos abeta amiloides oligomericos; polinucleotidos que codifican dicho anticuerpo; composicion terapeutica que comprende el anticuerpo; uso del anticuerpo para tratar enfermedades y trastornos causados o asociados a las proteinas amiloides (div. sol. 1742-2008).
AR092779A1 (es) Composicon farmaceutica que comprende anticuerpos que se unen a conformeros de proteinas tau
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
BR112017019300A2 (pt) conjugado de fórmula genérica ama - l - x - s - ab, método para sintetizar um conjugado de fórmula genérica ama - l - x - s - ab, kit, método para sintetizar o composto ama - l - x', composição farmacêutica e método para tratar uma doença associada a células que apresentam um alvo
ECSP13012609A (es) Composición farmacéutica
ECSP088750A (es) Métodos y composiciones para antagonismo de rage
CR10561A (es) Vacunas para malaria
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
UY32341A (es) Proteínas de unión antígeno novedosas
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
BR112018072681A2 (pt) anticorpos anti-il-1r3 humanizados
CR20120491A (es) Proteinas de unión a antigeno especificas para el componente amiloide serico p
CO2018000414A2 (es) Inmunoconjugados de il22
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
BR112014029089A2 (pt) anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2